Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects

Pharmacotherapy
L K Golightly

Abstract

Pindolol is a new noncardioselective beta adrenergic blocking agent with intrinsic sympathomimetic activity. In the treatment of mild to moderate hypertension, pindolol provides effective control of blood pressure in a large majority of patients when administered alone or, more commonly, when combined with a thiazide diuretic. Pindolol is approximately as effective as propranolol in the therapy of hypertension, but in some crossover trials central nervous system side effects were more frequent with pindolol. A "ceiling effect" may be observed as dosages are titrated upward above approximately 20 to 30 mg per day, such that further blood pressure reductions may not be achievable. Some patients will exhibit a paradoxical increase in blood pressure with an increase in dosage. In patients who respond to modest doses of pindolol, twice or even once daily dosing is often adequate. This prolonged duration of hypotensive activity, while not suggested by the kinetics of this or similar drugs, is probably common to most beta blockers. Investigations in small numbers of patients with angina pectoris have reported variable but generally beneficial results with pindolol.

References

Aug 1, 1990·British Journal of Clinical Pharmacology·D G Waller
Jul 1, 1984·Medicinal Research Reviews·M Simonyi
Oct 13, 2005·The Annals of Pharmacotherapy·Patrick B WoodGloria S Caldito

Citations

Aug 5, 1976·The New England Journal of Medicine·R J Lefkowitz
Dec 1, 1976·Drugs·H J Waal-Manning
Jan 1, 1976·Clinical Pharmacokinetics·G Johnsson, C G Regàrdh
Mar 1, 1977·American Heart Journal·L Hansson, L Werkö
Feb 1, 1978·British Journal of Clinical Pharmacology·D G McDevitt
Apr 1, 1978·Drugs·M Anthony
May 1, 1978·British Journal of Clinical Pharmacology·M K BensonG S Sterling
Feb 1, 1979·Journal of Clinical Pharmacology·L VolicerH R Brunner
Jan 1, 1979·Annual Review of Pharmacology and Toxicology·A Scriabine
Mar 1, 1979·Drugs·H J Waal-Manning
Jun 12, 1979·European Journal of Clinical Pharmacology·L A SalakoR A Adio
Jan 1, 1979·British Journal of Clinical Pharmacology·K O Stumpe, O Overlack
Jan 1, 1979·British Journal of Clinical Pharmacology·M M El-MehairyS S Tadros
Sep 27, 1979·The New England Journal of Medicine·J Koch-Weser
Apr 1, 1975·European Journal of Pharmacology·J F GiudicelliJ R Boissier
Sep 1, 1975·European Journal of Pharmacology·H L Garvey, N Ram
Sep 1, 1978·The Annals of Thoracic Surgery·H BoudoulasJ S Vasko
May 1, 1977·Clinical Pharmacology and Therapeutics·Y M Traub, J B Rosenfeld
Feb 1, 1978·The Annals of Thoracic Surgery·M M KirshH Sloan
Jan 1, 1978·Cardiology·T J Bloem, J V Kerkhof
Mar 17, 1978·European Journal of Clinical Pharmacology·C C ChristensenG Hansen
May 27, 1978·British Medical Journal·T ReybrouckE Meulepas
Jan 1, 1978·Acta Medica Scandinavica·F GyntelbergB Harvald
Jan 1, 1978·The Journal of International Medical Research·N Jaroonvesma, K Charoenlarp
Nov 27, 1978·European Journal of Clinical Pharmacology·A P Douglas-JonesA Lee
Jan 1, 1979·The British Journal of Ophthalmology·S E SmithV B Whitmarsh
Apr 1, 1979·Clinical Pharmacology and Therapeutics·B E KarlbergU Waern
Oct 1, 1977·European Journal of Clinical Investigation·I TényiJ Czimer
Mar 1, 1979·American Heart Journal·M G MyersG Wisenberg
Mar 1, 1979·British Journal of Clinical Pharmacology·G L JenningsP I Korner

Related Concepts

Visken
Brain
Betalok
Sembrina
Entire Central Nervous System
Hypotension, Orthostatic
Adverse Effects
Thyroid Diseases
Pulmonary Vascular Resistance
Thiazide Diuretics

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.